Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 1
1(25.0%)
4Total
N/A(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06285253Phase 1Completed

miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial

Role: lead

NCT03232333Completed

MIRODERM H2H DFU Study

Role: lead

NCT03735862Completed

Complications, Outcomes and Revisions Following Hiatal Hernia Repair With MIROMESH

Role: lead

NCT02436681Not ApplicableCompleted

Miromatrix Biological Mesh for Hiatal Hernia Repair

Role: lead

NCT02408458Not ApplicableWithdrawn

Miromatrix Biological Mesh for Ventral Hernia Repair

Role: lead

NCT02732548Not ApplicableWithdrawn

MIRODERM™ for Complex Wounds in an Inpatient Setting (MIRODERM CLOSure)

Role: lead

All 6 trials loaded